Initially, Mendelian Randomization (MR) analyses were conducted to explore causal associations between genes in the sphingolipid metabolism pathway and IPF, which led to the identification of SPHK1 as a potential therapeutic target. The gene discussed is SPHK1; the disease is idiopathic pulmonary fibrosis.